<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83380">
  <stage>Registered</stage>
  <submitdate>20/11/2008</submitdate>
  <approvaldate>20/02/2009</approvaldate>
  <actrnumber>ACTRN12609000125224</actrnumber>
  <trial_identification>
    <studytitle>Topical use of immunosupressor,Tacrolimus, in desquamative gingivitis patients: an open trial.</studytitle>
    <scientifictitle>Use of topical immunosupressant,Tacrolimus, in desquamative gingivitis patients: evaluation of effectiveness according to individual and disease characteristics.</scientifictitle>
    <utrn />
    <trialacronym>Immunosupressants and desquamative gingivitis</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Desquamative gingivitis</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Autoimmune diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The patient will be shaped to get a plate of silicon on top of the model study, after will be delivered promptly to the patient with a tube of medication with Tacrolimus 0.1% gel, the patient will be guided in making the application through the trays that have the gel in it and take position in the mouth for 5 minutes twice a day for 90 days.</interventions>
    <comparator>No treatment</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Effectiveness or lack of effectiveness followed through a chart that identifies presence and intensity of clinical signs (like ulcers, vesicles and erithema). Pain and discomfort will be checked by means of a Visual analogue scale (VAS).</outcome>
      <timepoint>VAS prior to drug delivery, 45-day and at the end of the period (90 day).
Clinical follow-up: starting point and every 15 days up to the end of 90-day period.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The results and effectiveness of the medication will be evaluated according to the type of disease by the professional researcher to compare the photos, using the VAS scale and the patient's complaint</outcome>
      <timepoint>45 and 90 days after the starting point.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients exhibiting desquamative gingivitis with consent agreement.
There will be no exclusion by gender, age, or race, only if the patient is carrying a change of renal or hepatic</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>the patient with renal failure and / or liver</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/09/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Sao Paulo</primarysponsorname>
    <primarysponsoraddress>Lineu Prestes Av, 2227 - University City - S達o Paulo / SP</primarysponsoraddress>
    <primarysponsorcountry>Brazil</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry>Brazil</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>General Hospital of Uniersity of Sao Paulo</othercollaboratorname>
      <othercollaboratoraddress>Eneas de Carvalho Aguiar, 255 - Cerqueira Cesar - Sao Paulo/SP</othercollaboratoraddress>
      <othercollaboratorcountry>Brazil</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The main purpose of this trial is to assess the therapeutic efficacy of tacrolimus, in topical use, to the symptomatic treatment of desquamative gingivitis.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>University of Sao Paulo, Dentistry School Ethics Committee</ethicname>
      <ethicaddress>Lineu Prestes Av, 2227 - University City - Sao Paulo / SP</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>1/12/2008</ethicsubmitdate>
      <ethiccountry>Brazil</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dante Antonio Migliari</name>
      <address>Lineu Prestes Av, 2227 - University City - S達o Paulo / SP</address>
      <phone>55-11-30917883</phone>
      <fax />
      <email>damiglia@usp.br</email>
      <country>Brazil</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Anna Torrezani</name>
      <address>Abel Seixas Street, 76 - Santo Amaro - S達o Paulo/SP</address>
      <phone>55-11-55226845</phone>
      <fax />
      <email>annatorrezani@ig.com.br</email>
      <country>Brazil</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Anna Torrezani</name>
      <address>Abel Seixas Street, 76 - Santo Amaro - S達o Paulo/SP</address>
      <phone>55-11-55226845</phone>
      <fax />
      <email>annatorrezani@ig.com.br</email>
      <country>Brazil</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>